Drug Profile
Bruton's tyrosine kinase inhibitor - Pharmacyclics
Alternative Names: BTK Inhibitor - PharmacyclicsLatest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator Pharmacyclics
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 26 May 2015 Pharmacyclics has been acquired by AbbVie